I heard about this on the radio on my way home and I was so pumped. I’ve been wondering for weeks why trump has been silent on all the “anecdotal” stories about hydroxy and zinc. No doubt there will be some forthcoming studies to back up the prophylactic benefits. The only problem I see is that you are not supposed to drink if on hydroxy. I think a lot of Americans will take their chances and keep the beer.
Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19(includes risk table)
...Chloroquine, and its more contemporary derivative hydroxychloroquine, have remained in clinical use for more than a half-century as an effective therapy for treatment of some malarias, lupus, and rheumatoid arthritis. Data show inhibition of iKr and resultant mild QT prolongation associated with both agents.
Despite these suggestive findings, several hundred million courses of chloroquine have been used worldwide making it one of the most widely used drugs in history, without reports of arrhythmic death under World Health Organization surveillance.4
Nonetheless, the absence of an active drug safety surveillance system in most countries limits reassurance from these observations.
Azithromycin, a frequently used macrolide antibiotics lacks strong pharmacodynamic evidence of iKr inhibition. Epidemiologic studies have estimated an excess of 47 cardiovascular deaths which are presumed arrhythmic per 1 million completed courses, although recent studies suggest this may be overestimated.6-7
There is limited data evaluating the safety of combination therapy, however in vivo studies have shown no synergistic arrhythmic effects of azithromycin with or without chloroquine.8
A number of factors are known to contribute to increased risk of drug-induced TdP including female sex, structural heart disease, congenital long-QT syndromes, electrolyte disturbances, hepatic/renal failure and concomitant QT prolonging medications.6
The safety of QT prolonging medications may be maximized by close monitoring and optimization of these factors. A risk score has been derived and validated by Tisdale et al., for prediction of drug-associated QT prolongation among cardiac-care-unit-hospitalized patients (Table 1).9